Iron Overload

1
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
2 programs
1
DesferasiroxPhase 41 trial
Iron Overload in Pediatric Oncology PatientsN/A1 trial
Active Trials
NCT01034072Completed75Est. Jan 2012
NCT01546415Completed64Est. Nov 2013
One Biosciences
One BiosciencesFrance - Paris
1 program
R2*-UTEN/A1 trial
Active Trials
NCT01572922CompletedEst. Feb 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisDesferasirox
One BiosciencesR2*-UTE
NovartisIron Overload in Pediatric Oncology Patients

Clinical Trials (3)

Total enrollment: 139 patients across 3 trials

NCT01546415NovartisDesferasirox

Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia

Start: Oct 2011Est. completion: Nov 201364 patients
Phase 4Completed
NCT01572922One BiosciencesR2*-UTE

Massive Iron Deposit Assessment

Start: Jun 2012Est. completion: Feb 2018
N/ACompleted
NCT01034072NovartisIron Overload in Pediatric Oncology Patients

Iron Overload in Pediatric Oncology Patients

Start: Dec 2009Est. completion: Jan 201275 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 companies competing in this space